选择性脾胃区减断术与脾切除联合贲门周围血管离断术治疗肝硬化并发门静脉高压症患者疗效对照研究*

doi:10.3969/j.issn.1672-5069.2025.02.020

摘要/Abstract

摘要： 目的比较研究选择性脾胃区减断术(SDD-GSR)与脾切除联合贲门周围血管离断术(SPD)治疗肝硬化并发门静脉高压症(PHT)患者的效果差异。方法 2019年1月～2024年1月我院收治的65例PHT患者,其中32例观察组接受SDD-GSR治疗,33例对照组接受SPD治疗。采用玻璃管水柱测压计检测胃网膜右静脉门静脉压力;使用超声诊断仪检测门静脉血流量(PVF)、门静脉直径(PVD)和门静脉血流流速(PVV);使用流式细胞仪检测外周血T淋巴细胞亚群。结果在治疗结束后,观察组门脉压力为(21.1±4.2)cmH₂O,显著低于对照组【(25.7±5.3)cmH₂O,P<0.05】;在手术后3个月,观察组PVD为(1.3±0.3)cm,显著小于对照组【(1.5±0.4)cm,P<0.05】,而PVV为(47.7±3.5)cm/s,显著快于对照组【(41.0±3.1)cm/s,P<0.05】;手术前后,两组血清肝功能指标和外周血血细胞计数比较,差异无统计学意义(P>0.05); 在治疗后3个月,观察组外周血CD4⁺细胞百分比和CD4⁺/CD8⁺比值分别为(41.9±3.4)%和(1.4±0.3),显著高于对照组【分别为(35.6±3.1)%和(1.2±0.2),P<0.05】。结论作为新兴的手术,采取SDD-GSR治疗肝硬化并发PHT患者近期疗效好,在改善门静脉血流动力学和免疫功能指标方面可能具有更好的优势,值得进一步探讨。

关键词: 肝硬化, 门静脉高压症, 选择性脾胃区减断术, 脾切除联合贲门周围血管离断术, 治疗

Abstract: Objective The aim of this study was to compare efficacy selective decongestive devascularization of gastrosplenic region (SDD-GSR) and splenectomy and pericardial devascularization (SPD) combination in the treatment of cirrhotics with portal hypertension (PHT). Methods Sixty-five patients with cirrhotic PHT were encountered in our hospital between January 2019 and January 2024, and out of them, 32 patients in observation group received SDD-GSR and 33 in control received SPD. Portal vein pressure was measured by glass water column manometer through right gastroepiploic vein. Portal vein flow (PVF), portal vein diameter (PVD) and portal vein velocity (PVV) were determined by color Doppler ultrasound. Peripheral blood T lymphocyte subsets were detected by flow cytometry. Results By end of surgery, the portal vein pressure in the observation group was (21.1±4.2) cmH₂O, much lower than [(25.7±5.3) cmH₂O, P<0.05] in the control group; by end of three months after operation, the PVD in the observation was (1.3±0.3)cm, much smaller than [(1.5±0.4)cm, P<0.05], while the PVV was (47.7±3.5)cm/s, much quicker than [(41.0±3.1)cm/s, P<0.05] in the control; before and after operation, there were no significant differences as respect to liver function tests and blood cell counts between the two groups (P>0.05); by three months after operation, percentage of peripheral blood CD4⁺ cells and CD4⁺/CD8⁺ cell ration in the observation group were (41.9±3.4)% and (1.4±0.3), both significantly higher than [(35.6±3.1)% and (1.2±0.2), respectively, P<0.05] in the control group. Conclusion The SDD-GSR operation has a satisfactory efficacy in the treatment of cirrhotic PTH, with improvement of portal vein hemodynamics and immune functions, which warrants further clinical investigation.

Key words: Liver cirrhosis, Portal hypertension, Selective decongestive devascularization of gastrosplenic region, Splenectomy and pericardial devascularization, Therapy

何晓非, 陈杰, 赵斌, 陆世峰. 选择性脾胃区减断术与脾切除联合贲门周围血管离断术治疗肝硬化并发门静脉高压症患者疗效对照研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 238-241.

He Xiaofei, Chen Jie, Zhao Bin, et al. A comparative study of selective decongestive devascularization of gastrosplenic region and splenectomy and pericardial devascularization combination in the treatment of patients with cirrhotic portal hypertension[J]. Journal of Practical Hepatology, 2025, 28(2): 238-241.

参考文献

[1] Liu B, Zhang D, Dong C,et al. Correlation between hepatic venous pressure gradient and portal pressure gradient in patients with autoimmune cirrhotic portal hypertension and collateral branches of the hepatic vein. Hepatol Res, 2023, 53(11):1084-1095.
[2] Wang Y, Zhang G, Mu X, et al. Diagnostic value of magnetic resonance elastography in cirrhotic portal hypertension. J Hepatol, 2020, 73(2):S532-S533.
[3] 李嘉兴,伍丽霞,尹承龙,等.腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压并发食管胃底静脉曲张患者疗效研究.实用肝脏病杂志, 2023, 26(2):258-261.
[4] 段建文,余华军,叶海林,等.选择性脾胃区减断术治疗肝硬化门静脉高压症的临床价值分析.中华肝胆外科杂志, 2021, 27(7)::525-528.
[5] Shin S, Suh DI, Ko JM, et al. Combined lung and liver transplantation for noncirrhotic portal hypertension with severe hepatopulmonary syndrome in a patient with dyskeratosis congenital. Pediatr Transplant, 2021, 25(2):e13802.
[6] Madoff DC, Cornman-Homonoff J, Fortune BE, et al. Management of refractory ascites due to portal hypertension: current status. Radiology, 2021, 298(3):493-504.
[7] 中华医学会肝病学分会.肝硬化诊治指南.中华肝脏病杂志, 2019, 27(11):846-865.
[8] Deng Y, Jiang Y, Jiang T, et al. Evaluation of the efficacy and safety of endoscopic band ligation in the treatment of bleeding from mild to moderate gastric varices type 1. World J Gastroenterol, 2024, 30(5):440-449.
[9] Lejealle C, Valérie Paradis, Bouattour M, et al. Relationship between laennec histological subclassification of cirrhosis and clinical stage, grade of portal hypertension and liver stiffness. J Hepatol, 2020, 73(4):S781.
[10] Sato A, Watanabe S, Iseki M, et al. Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis‐related complications: A propensity score‐matched study. Hepatol Res, 2023, 53(11):1096-1104.
[11] Barnes A, Cock C. Rapid reversal of hyponatraemia in a patient with non‐cirrhotic portal hypertension treated with terlipressin. Intern Med J, 2020, 50(2):254-255.
[12] Lemoine CP, Superina R. Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension? Hepatology, 2022, 76(2):32386.
[13] Roncati L, Manenti A, Gasparri P, et al. Portopulmonary hypertension correlated with portal vein overload. Ann Vasc Surg, 2020, 65(5):e300-e301.
[14] Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut, 2020, 69(7):1173-1192.
[15] Simbrunner B, Marculescu R, Scheiner B, et al. Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int, 2020, 40(7):1713-1724.
[16] Zheng D, Yu J, Li H, et al. Effects of transjugular intrahepatic portosystemic shunt treatment of patients with liver cirrhosis and portal hypertension: Case series.Medicine, 2021, 100(27):e26610.
[17] Anand U, Kumar R, Priyadarshi R. Proximal splenorenal shunt as a secondary prophylaxis for isolated gastric bleeding in patients with non-cirrhotic portal hypertension: a report from a single-center case-series. J Hepatol, 2020, 73(3):S281-S285.
[18] Jothimani D, Rela M, Kamath PS. Livercirrhosis and portal hypertension: How to deal with esophageal varices? Med Clin North Am, 2023, 107(3):491-504.
[19] Tedeschi M, Ciacio O, Golse N, et al. Porto-caval shunt is a salvage manoeuvre to reduce de novo portal hypertension after major hepatectomy. HPB, 2021, 23(1):S166.
[20] 汪昱,董科.改良腹腔镜脾脏切除+贲门周围血管离断术在肝硬化合并门静脉高压症中的应用研究.中华普外科手术学杂志:电子版, 2021, 15(1):65-68.

选择性脾胃区减断术与脾切除联合贲门周围血管离断术治疗肝硬化并发门静脉高压症患者疗效对照研究^*

A comparative study of selective decongestive devascularization of gastrosplenic region and splenectomy and pericardial devascularization combination in the treatment of patients with cirrhotic portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	崔冶齐, 张世斌. 肝硬化门静脉血栓分类及形成机制研究进展^*[J]. 实用肝脏病杂志, 2025, 28(2): 161-164.
[2]	吕天富, 南琼. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症患者抗凝治疗研究进展[J]. 实用肝脏病杂志, 2025, 28(2): 165-168.
[3]	陈婷婷, 丁蓉, 姬文莉, 吴梦秋. 高敏HBV DNA检测技术在低病毒血症慢性乙型肝炎患者抗病毒疗效监测中的应用^*[J]. 实用肝脏病杂志, 2025, 28(2): 178-181.
[4]	钱花, 杨忠祥, 石荔. 核苷(酸)类似物经治的慢性乙型肝炎患者发生低病毒血症影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 186-189.
[5]	祁婧, 赵小婷, 王婷婷, 高瑞. 接受索磷布韦/达拉他韦治疗的慢性丙型肝炎患者血清NOD样受体热蛋白结构域相关蛋白3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(2): 194-197.
[6]	钱平安, 姜煜资, 聂红明. 穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 206-209.
[7]	管海燕, 张慧, 张毅, 王晓兰, 吴婷婷. 肝脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎患者治疗应答的影响^*[J]. 实用肝脏病杂志, 2025, 28(2): 214-217.
[8]	孙超, 宋丽萍, 王彬. 异甘草酸镁联合还原型谷胱甘肽治疗化疗药物性肝损伤患者疗效及其血清氧化应激指标的变化研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 222-225.
[9]	拾倩, 李莉, 倪昊天. 替诺福韦联合安络化纤丸治疗乙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 242-245.
[10]	刘成环, 刘刚, 甘郑宁, 尹桂秀, 李伟霞. 磁共振FRFSE联合多模态影像学技术评估脾脏Gamna-Gandy小体预测乙型肝炎肝硬化患者并发食管胃底静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 246-249.
[11]	程晓洁, 彭星华, 葛海江, 程海超, 张明, 李智峰. 脾栓塞术治疗肝豆状核变性并发中重度脾功能亢进症患者疗效评价^*[J]. 实用肝脏病杂志, 2025, 28(2): 250-253.
[12]	陈思雨, 庞永平, 宋云鹏, 乔海霞. TACE联合靶向和免疫治疗中晚期肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 258-261.
[13]	严隽瑶, 尹国文, 徐清宇, 尤然, 秦锦霞. 阿替利珠单抗联合射频消融术治疗不可切除的肝细胞癌患者临床疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 262-265.
[14]	钟新梅, 闫莉莉, 张冬梅. 细菌性肝脓肿患者临床特征与病原菌分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 286-289.
[15]	翟鹏, 张华国, 蒋永军. 腹腔镜与胆道镜双镜联合治疗复发性胆总管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 306-309.